MedTrace Logo

Behavioral Activation and HIV Risk Reduction for Men Who Have Sex With Men With Crystal Meth Abuse

NCT01255280 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-06-01

No results posted yet for this study

Summary

The purpose of this study is to research a new behavioral treatment to reduce sexual risk-taking in men who have sex with men (MSM) who abuse crystal methamphetamine (crystal meth), and are at risk for HIV acquisition. This study proposes using a treatment based on our original pilot study that incorporates risk reduction and behavioral activation therapy. In order to help learn what types of treatment programs best help individuals who abuse crystal meth and engage in sexual risk-taking, we will compare our treatment to a control group. The treatment group will receive therapy incorporating behavioral risk reduction counseling with behavioral activation therapy to treat depression, helping individuals reengage in their life. The control group will receive the risk reduction counseling without the behavioral activation therapy. The current study hopes to explore the efficacy of this previous developed treatment in a two-arm pilot randomized controlled trial.

Conditions

  • Crystal Methamphetamine Abuse
  • Crystal Methamphetamine Dependence

Interventions

BEHAVIORAL

Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)

This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.

BEHAVIORAL

Information, Motivation, Behavioral skills change approach to sexual risk reduction

The comparison condition will only receive the two IMB risk reduction sessions.

Sponsors & Collaborators

  • Fenway Community Health

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Matthew Mimiaga, ScD · Fenway Community Health and Massachusetts General Hospital/Harvard Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01255280 on ClinicalTrials.gov